EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Optimal Lung Cancer Ct Screening Strategy: A Cost‐Effectiveness Study Incorporating Nelson Evidence, Evolving Cost of Treatment and Smoking Cessation Interventions

Koen de Nijs iD, Kevin Ten Haaf iD, Dana Moldovanu, Juul Hubert, Isabelle van den Bosch, Carlijn van der Aalst, Harry J de Koning iD

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70655 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Koen de Nijs und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, Erasmus MC-University Medical Center Rotterdam, Rotterdam, CE, the Netherlands. Hauptthemen laut MEDLINE: Lung Neoplasms, Smoking Cessation, Early Detection of Cancer, Tomography, X-Ray Computed. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HORIZON EUROPE Health, Nederlandse Organisatie voor Wetenschappelijk Onderzoek.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer screening implementation is taking shape worldwide. Programme design requires specifying eligibility criteria, screening interval, and the optimal age range. We estimate benefits and harms of competing strategies, integrating NELSON results, smoking cessation interventions, contemporary treatment costs, and the management of feasible CT capacity. 1080 strategies are evaluated using the MISCAN‐Lung microsimulation model, calibrated to NELSON and NLST data. 1945–1979 Dutch cohorts are simulated using a representative smoking history generator. For each strategy, the (cost‐)effectiveness is evaluated, as well as CT requirements and the incremental benefit of a smoking cessation intervention (pharmacotherapy). Lung cancer screening was found to be cost‐effective overall. Risk‐based recruitment (PLCOm2012) is more efficient than pack‐year‐based criteria. Annual screening ages 55–75 from > 1.5% lung cancer risk is cost‐efficient (ICER < €20 k), and would cost €12,201 per quality‐adjusted life‐year (QALY) relative to no screening (or €19,713 compared to less intensive screening). Population‐wide, lung cancer mortality would be reduced by 10.8% (1072 cases/year) at full uptake, or by 6.2% at 50% uptake. For the first three years, at 50% uptake of screening, the strategy requires a 16.1% increase of national CT volume. Nearly half of CT costs are offset by reductions in terminal care expenditures. Integrated smoking cessation is cost‐effective at €10,043/QALY (relative to screening without integrated cessation), yielding 32% additional life‐years gained. Lung cancer screening is increasingly cost‐effective and may be critically considered for implementation, including integrated smoking cessation. We find annual screening ages 55–75 for those > 1.5% (PLCOm) risk to be within a €20 k willingness‐to‐pay and feasible CT requirements.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsSmoking CessationEarly Detection of CancerTomography, X-Ray ComputedHumansCost-Benefit AnalysisCost-Effectiveness AnalysisMiddle AgedAgedFemaleQuality-Adjusted Life YearsMaleNetherlandsSmokingMass Screening

Stichwörter der Autor:innen

cancer early detectioncomputed tomographycost‐effectiveness analysislung cancermass screening

Autor:innen und Institutionen

  • Department of Public Health, Erasmus MC-University Medical Center Rotterdam, Rotterdam, CE, the Netherlands.

ORCID-Profile: Koen de Nijs, Kevin Ten Haaf, Harry J de Koning

Förderung

  • HORIZON EUROPE Health
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek

Zitieren

APA

de Nijs, K., Ten Haaf, K., Moldovanu, D., Hubert, J., van den Bosch, I., van der Aalst, C., & de Koning, H. J. (2026). The Optimal Lung Cancer Ct Screening Strategy: A Cost‐Effectiveness Study Incorporating Nelson Evidence, Evolving Cost of Treatment and Smoking Cessation Interventions. International Journal of Cancer. https://doi.org/10.1002/ijc.70655

Vancouver

de Nijs K, Ten Haaf K, Moldovanu D, Hubert J, van den Bosch I, van der Aalst C, et al. The Optimal Lung Cancer Ct Screening Strategy: A Cost‐Effectiveness Study Incorporating Nelson Evidence, Evolving Cost of Treatment and Smoking Cessation Interventions. International Journal of Cancer. 2026. doi:10.1002/ijc.70655

BibTeX
@article{deNijs2026,
  author = {de Nijs, Koen and Ten Haaf, Kevin and Moldovanu, Dana and Hubert, Juul and van den Bosch, Isabelle and van der Aalst, Carlijn and de Koning, Harry J},
  title = {The Optimal Lung Cancer Ct Screening Strategy: A Cost‐Effectiveness Study Incorporating Nelson Evidence, Evolving Cost of Treatment and Smoking Cessation Interventions},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70655}
}
Kostenlos starten →